Testing new immune cells plus chemo for advanced colon cancer
Part of Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests CYAD-101, an immune-cell treatment made from donor T-cells, given with standard chemotherapy. It is for people with colon or rectal cancer that has spread and has not responded to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed colon or rectal adenocarcinoma that has spread and cannot be fully removed with surgery
- Your cancer must have worsened after at least one prior treatment for metastatic disease
- Your prior chemotherapy matches one of these patterns: FOLFOX must have caused nerve side effects no worse than mild (Grade 1)
- You had FOLFIRI treatment, and your cancer kept growing during or shortly after it (within the last 3 months)
- You are well enough for treatment (ECOG performance status 0 or 1) and your organs and blood counts are adequate
- You do not have brain or spinal cord involvement from cancer (CNS involvement)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether adding pembrolizumab after CYAD-101 and FOLFOX chemotherapy can help treat metastatic colon or rectal cancer. It is mainly looking for safety and signs of how well the treatment works in people whose cancer has not responded to prior therapy.
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
This trial tests whether a stronger chemo combination plus an immunotherapy drug (PD-1 inhibitor) works better than standard chemo alone when given before surgery for locally advanced colon cancer. It aims to shrink the tumor and improve outcomes.
This Phase 1/2 trial tests LYL273, a new targeted treatment, for people with metastatic colorectal (colon) cancer that has returned or not responded to standard chemo. It’s designed to see how well the drug can control the cancer and what side effects it causes.
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced colorectal cancer.
Hear when a new Unresectable Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.